Steatohepatitis
| Steatohepatitis | |
|---|---|
| Diagnosis in short | |
|
Steatohepatitis. Trichrome stain. | |
|
| |
| LM | steatosis (usually macrovesicular); hepatocyte injury -- ballooning degeneration (key feature), Mallory bodies; portal bridging (late stage) |
| Subtypes | by etiology (classically): ASH, NASH -- all almost histologically identical |
| LM DDx | steatosis, Wilson disease, hepatitis C, drug-induced liver disease |
| Gross | pale/yellowish, often enlarged |
| Site | liver - see medical liver disease |
|
| |
| Associated Dx | obesity, alcohol abuse |
| Prevalence | common |
| Prognosis | dependent on underlying cause |
| Treatment | dependent on underlying cause |
Steatohepatitis is a fatty change of the liver (steaosis) with (histologic) evidence of liver injury. It can be due to a number of different causes.
General
- Steatohepatitis is a label for a set of histopathologic findings.
- Fat accumulation (in hepatocytes) alone is liver steatosis.
- It may be a pattern seen in drug toxicity, e.g. methotrexate toxicity.[1]
Etiology:
- Alcohol = alcoholic steatohepatitis (ASH).
- Not alcohol = non-alcoholic steatohepatitis (NASH).
- Drug/toxin.[2]
Notes:
- Pathologists can comment on the etiology; however, the histomorphology is not distinctive. In other words, ASH and NASH are clinical diagnoses.
- Steatohepatitis is a misnomer. It is not an -itis; inflammation is not the (predominant) pathologic process.
Microscopic
Features:
- Steatosis (usually macrovesicular) - key feature.
- If less than 10% ... consider alt. diagnosis/disease process.
- Hepatocyte injury:
- Ballooning degeneration - key feature. †
- Mallory bodies.
- Mallory body wannabes: "occasional cytoplasmic clumping".
- +/-Chicken-wire perisinusoidal fibrosis +/- zone III (centrilobular) fibrosis (early).
- Late-stage disease - portal bridging.[3]
Note:
- † Brunt does not require ballooning to be present to call steatohepatitis;[4] however, a table in a later paper Brunt paper (surveying pathologists) suggest that a significant number of pathologist may consider it a required finding.[5]
DDx:
- Steatosis - lacks ballooning degeneration and neutrophils.
- Wilson disease.
- Hepatitis C.
- Drug-induced liver disease.
Image
-
Steatohepatitis. (WC)
Grading steatohepatitis
A simple grading system
| Grade | Characteristics |
|---|---|
| 1 | steatosis, occasional ballooning, scattered PMNs |
| 2 | steatosis, obvious ballooning, obvious PMNs, chronic inflammation |
| 3 | panacinar steatosis, obvious ballooning |
Brunt grading system
Brunt's 1999 paper proposed a system:[4]
| Grade | Steatosis | Neutrophils | Ballooning | Chronic inflammation |
|---|---|---|---|---|
| 1 | <=66% | scattered, rare | occasional or absent (zone 3) | none or mild acinar, none or mild portal |
| 2 | any amount (>33%) | present | obvious ballooning | mild or moderate acinar, mild or moderate portal |
| 3 | panacinar, zone 3 predominant | present | present, obvious | mild acinar inflammation, mild or moderate (not marked) portal |
Clinical Research Network system
Nonalcoholic steatohepatitis Clinical Research Network system for scoring activity - adapted from Brunt and Tiniakos:[6]
| Score | Steatotic hepatocytes (%) |
Foci of lobular lymphocytes |
Ballooning heptocytes |
|---|---|---|---|
| 0 | <5% | none | none |
| 1 | 5-33% | <2 | few |
| 2 | 34%-66% | 2-4 | many |
| 3 | >66% | >4 | (not assigned) |
Staging steatohepatitis
| Stage | Fibrosis | Notes |
|---|---|---|
| 0 | none | - |
| 1 | zone 3 perisinusoidal | may be focal or extensive |
| 2 | perisinusoidal and periportal | no bridging |
| 3 | bridging fibrosis | no nodule formation |
| 4 | nodule formation | - |
Images
Steatohepatitis. Brunt necroinflammatory grade 1. Brunt fibrosis stage 1. Steatosis afflicts about 30% of hepatocytes; note the absence of visible triads (Row 1 Left 20X). Cytoplasmic tufts of ballooning degeneration [violet arrows] were commonly found; a lymphohistiocytic aggregate [blue arrow], important for NAFLD, but not for Brunt, is seen (Row 1 Right 400X). A triad shows a vein [green arrow], an artery [red arrow], an interlobular duct [blue arrow], and proliferating bile ductules [cyan arrows]; only a few lymphocytes are seen (Row 2 Left 400X). Central vein shows only a few endothelial cells, with somewhat packed hepatocytes surrounding it (Row 2 Right 400X). Trichrome shows mostly space of Disse fibrosis [black arrows], sometimes adjoining hepatocytes [green arrows] show this is a stage 1 fibrosis (Row 3 Left 400X). Trichrome shows a central vein with a minimum of sclerosis; an interhepatocyte fibrous extension [arrow] displays the very beginning of fibrosis (Row 3 Right 400X).
Steatohepatitis Brunt necroinflammatory grade 3, Brunt fibrosis stage 1 (not shown). Panacinar steatosis with unremarkable, small triads (Row 1 Left 40X). Ballooning degeneration, with cytoplasmic tufts [arrows] (Row 1 Right 400X). Lipogranuloma (Row 2 Left 400X). Triad with mild chronic inflammation without interface hepatitis (Row 2 Right 400X).
Steatohepatitis. Brunt necroinflammatory grade 3, Brunt fibrosis stage 3. Steatosis afflicts almost all hepatocytes (pan-acinar) (Row 1 Left 40X). An isolated septal duct with concentric fibrosis [arrow] should not result in a diagnosis of primary sclerosing cholangitis. The woman who underwent the biopsy had a normal bilirubin level, a normal alkaline phosphatase level, and only slightly elevated transaminase levels. (Row 1 Right 200X). Cytoplasmic tufts [arrows] prove ballooning degeneration (Row 2 Left 400X). PAS with diastase shows PAS-D Kupffer cells (arrows) (Row 2 Right 400X). Reticulin shows thick black lines [red arrows] of collapse, without portal central bridging. The apparent loss of reticulin due to steatosis [double head cyan arrow] should not be considered regeneration or hepatoma (Row 3 Left 200X). Trichrome shows a bridge [arrow] (Row 3 Right 200X).
See also
References
- ↑ Schumacher, JD.; Guo, GL. (Nov 2015). "Mechanistic review of drug-induced steatohepatitis.". Toxicol Appl Pharmacol 289 (1): 40-7. doi:10.1016/j.taap.2015.08.022. PMID 26344000.
- ↑ Farrell, GC. (2002). "Drugs and steatohepatitis.". Semin Liver Dis 22 (2): 185-94. doi:10.1055/s-2002-30106. PMID 12016549.
- ↑ Gramlich, T.; Kleiner, DE.; McCullough, AJ.; Matteoni, CA.; Boparai, N.; Younossi, ZM. (Feb 2004). "Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.". Hum Pathol 35 (2): 196-9. PMID 14991537.
- ↑ 4.0 4.1 Brunt, EM.; Janney, CG.; Di Bisceglie, AM.; Neuschwander-Tetri, BA.; Bacon, BR. (Sep 1999). "Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.". Am J Gastroenterol 94 (9): 2467-74. doi:10.1111/j.1572-0241.1999.01377.x. PMID 10484010.
- ↑ Brunt, EM. (2001). "Nonalcoholic steatohepatitis: definition and pathology.". Semin Liver Dis 21 (1): 3-16. PMID 11296695.
- ↑ Brunt, EM.; Tiniakos, DG. (Nov 2010). "Histopathology of nonalcoholic fatty liver disease.". World J Gastroenterol 16 (42): 5286-96. PMID 21072891.


